Investor Relations

Overview

Investor Relations

Overview

Century Therapeutics, Inc. is an innovative biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both hematological and solid tumor malignancies with significant unmet medical need. We have created a comprehensive allogeneic cell therapy platform that includes industry-leading induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, CRISPR-mediated precision gene editing that allows us to incorporate multiple transgenes and knock-outs to optimize cell product performance, sophisticated protein engineering capabilities to develop proprietary next generation chimeric antigen receptors (CARs), Allo-Evasion™ technology to prevent rejection of our cell products by the host immune system, and cutting edge manufacturing capabilities to minimize product development and supply risk. We believe that these vertically integrated capabilities will allow us to further expand our existing pipeline and develop highly differentiated iPSC-derived NK, or iNK, and T, or iT, therapeutics that may provide enhanced clinical outcomes compared to available therapeutic options. Our vision is to become a premier cell therapy company by developing and ultimately commercializing allogeneic cell therapies that dramatically and positively transform the lives of patients suffering from life-threatening cancers. To achieve our vision, we have assembled a world-class team whose members collectively have decades of experience in cell therapy and drug development, manufacturing, and commercialization.

Stay informed on Century news, including press releases, upcoming events and SEC filings

Stock Information

Oct 27, 2021

Data Provided by Refinitiv. Minimum 15 minutes delayed.